Also trades as: 0K1R.L (LSE) · $vol 0M
VRDN NASDAQ
Viridian Therapeutics, Inc.
1W: -5.3%
1M: +8.8%
3M: -43.2%
YTD: -48.0%
1Y: +23.4%
3Y: -31.8%
5Y: -5.3%
$15.97
-0.13 (-0.81%)
Pre-Market: $16.11 (+0.14, +0.88%)
Weekly Expected Move ±18.1%
$11
$14
$17
$20
$23
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$20.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.4B
52W Range12.795-34.29
Volume1,770,297
Avg Volume2,780,955
Beta0.82
Dividend—
Analyst Ratings
Company Info
CEOStephen F. Mahoney
Employees143
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-18
Websiteviridiantherapeutics.com
221 Crescent Street
Waltham, MA 02453
US
Waltham, MA 02453
US
617 272 4600
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Latest News
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
Viridian Therapeutics prices upsized $350M concurrent stock, and convertible notes offerings
12 Health Care Stocks Moving In Tuesday's Intraday Session
Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday
Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fairmount Funds Mana | P-Purchase | 1,176,470 | $17.00 | 2026-05-11 |
| Harmon Seth | F-InKind | 2,031 | $30.19 | 2026-03-03 |
| Beetham Thomas W. | F-InKind | 3,048 | $30.19 | 2026-03-03 |
| Tousignant Jennifer | F-InKind | 1,675 | $30.19 | 2026-03-03 |
| Mahoney Stephen F. | F-InKind | 7,408 | $30.19 | 2026-03-03 |